Physician profile
Constantine Vafidis
NPI 1467683227
$9,036.15
in general payments reported to CMS, 2019-2025
45 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $1,204 · 2021: $1,621 · 2022: $1,317 · 2023: $931 · 2024: $1,431 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,897.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,650.33 | 2019-2025 | Linzess, Ubrelvy, Creon |
| Astrazeneca Pharmaceuticals Lp | $1,141.56 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $891.63 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $873.21 | 2020-2023 | |
| Amgen INC. | $689.69 | 2019-2025 | Repatha, Otezla, Evenity |
| Biohaven Pharmaceuticals, INC. | $556.05 | 2020-2021 | |
| Glaxosmithkline, LLC. | $500.53 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Paratek Pharmaceuticals, INC. | $301.88 | 2024-2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $247.94 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $225.96 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $183.08 | 2024-2025 | Zoryve |
| Allergan, INC. | $172.90 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $153.41 | 2022 | |
| Novo Nordisk INC | $120.51 | 2022-2024 | Wegovy |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Vafidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.